Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin

@inproceedings{Karyekar2013ClinicallyRR,
  title={Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin},
  author={Chetan S. Karyekar and Robert C. Frederich and Shoba Ravichandran},
  booktitle={International journal of clinical practice},
  year={2013}
}
BACKGROUND In four 24-week controlled studies, the antihyperglycaemic efficacy of saxagliptin was demonstrated in patients with type 2 diabetes mellitus as add-on therapy to glyburide, a thiazolidinedione, or metformin, and when used in initial combination with metformin vs. metformin monotherapy in drug-naive patients. METHODS Data from these studies were analysed to compare the proportions of patients who achieved specific reductions from baseline in glycated haemoglobin [HbA(1c… CONTINUE READING